PPG introduces PPG LINQ Color software and PPG MAGICBOX body shop assistant for the refinish industry
PPG (NYSE: PPG) today announced the introduction of PPG LINQ™ Color software and the PPG MAGICBOX™ body shop assistant for smarter wireless mixing in automotive repair shops. The advanced tools are the latest components of the PPG LINQ end-to-end digital solution for the global refinish industry that provide productivity and sustainability improvement for body shops.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230830721690/en/
The PPG MAGICBOX™ smart device eliminates the need for specialized computers in the mixing room by delivering a PPG patented body shop assistant, connectable to new and existing USB scales in body shops. (Photo: Business Wire)
With PPG LINQ, refinish customers can streamline their repair process by using PPG’s cloud-based platform and its interconnected digital hardware, software and related services. The PPG MagicBox body shop assistant is a small but powerful device that communicates environmental conditions in mixing rooms and receives formulas direct from the PPG LINQ Color software. These new tools also extend the digital ecosystem to smaller body shops not previously served by the PPG LINQ solution.
The PPG LINQ system delivers benefits including faster color-matching from any internet-connected device; less rework and no need for spray-out cards; faster and more efficient paint mixing; and waste reduction, when compared to a traditional repair process.
“When our PPG LINQ digital ecosystem is paired with our industry-leading paint products, we can help body shop owners to realize a 15% ‘key-to-key’ productivity improvement,” said Chancey Hagerty, PPG senior vice president, Automotive Refinish. “From the time a customer leaves their key with a body shop until they return to collect their car, that body shop can achieve improved productivity, reduced waste and enhanced sustainability compared to a traditional repair approach.”
The launch of PPG LINQ Color software and the PPG MagicBox body shop assistant follows the launch of other PPG LINQ digital ecosystem products, including PPG VISUALIZID™ software, the PPG DIGIMATCH™ spectrophotometer and the PPG MOONWALK® system, the company’s award-winning, automated paint mixing system launched in 2019.
“Today, thousands of body shops around the globe already use the PPG MoonWalk, PPG VisualizID and PPG DigiMatch tools,” said Alban d’Epenoux, PPG global marketing director, Automotive Refinish. “The addition of PPG LINQ Color software and the PPG MagicBox device can also mean additional productivity and enhanced capabilities for those existing users and also for thousands of other body shops interested in adopting the best digital solutions to enhance their business performance.”
To learn more about the PPG LINQ digital solution, visit https://ppglinq.com.
PPG: WE PROTECT AND BEAUTIFY THE WORLD®
At PPG (NYSE:PPG), we work every day to develop and deliver the paints, coatings and materials that our customers have trusted for 140 years. Through dedication and creativity, we solve our customers’ biggest challenges, collaborating closely to find the right path forward. With headquarters in Pittsburgh, we operate and innovate in more than 70 countries and reported net sales of $17.7 billion in 2022. We serve customers in construction, consumer products, industrial and transportation markets and aftermarkets. To learn more, visit www.ppg.com.
PPG LINQ, MagicBox, Digimatch, and VisualizID are trademarks, and MoonWalk, the PPG Logo and We Protect and Beautify the World are registered trademarks of PPG Industries Ohio, Inc.
CATEGORY Automotive Refinish
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230830721690/en/
Contact information
Michelle Deemer
Automotive Refinish
+1 412 728 0195
mdeemer@ppg.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 11:00:00 EET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 11:00:00 EET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 11:00:00 EET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 10:00:00 EET | Press release
Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 09:44:00 EET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
